A Phase IIa trial of 177 Lutetium Dotatate in Children with Primary Refractory or Relapsed High-Risk Neuroblastoma

Trial Profile

A Phase IIa trial of 177 Lutetium Dotatate in Children with Primary Refractory or Relapsed High-Risk Neuroblastoma

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2018

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Acronyms LuDo
  • Most Recent Events

    • 10 Sep 2018 Status changed from recruiting to completed.
    • 03 Dec 2015 Accrual to date is 66% according to United Kingdom Clinical Research Network.
    • 23 Oct 2015 Accrual to date is 62% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top